<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113291</url>
  </required_header>
  <id_info>
    <org_study_id>DASHF-PRE</org_study_id>
    <nct_id>NCT04113291</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Pilot Trial of DASH Feeding in Older Low Socioeconomic Adults Without Heart Failure</brief_title>
  <acronym>DASHF</acronym>
  <official_title>Randomized Controlled Pilot Trial of Dietary Approached to Stop Hypertension (DASH) Feeding in Older Low Socioeconomic Adults Without Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the DASH diet (Dietary Approaches to Stop Hypertension) in the exploration
      of effective strategies for Heart failure (HF) with preserved ejection fraction (HFPEF)
      prevention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a feasibility pilot, randomized clinical trial (RCT), DASH diet feeding trial in 40
      older adults. It will also elicit trends in left ventricular remodeling and pathophysiology.
      This trial investigates the feasibility of performing a DASH diet RCT intervention in HFPEF
      prevention in older adults of low socioeconomic status (LSES).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of enrolled participants per week</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants that adhere to the to intervention</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number participants that were retained in the trial</measure>
    <time_frame>Up to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants that adhere to the diet</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Baseline</time_frame>
    <description>Weight (kilograms)</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Weight (kilograms)</description>
  </other_outcome>
  <other_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Baseline</time_frame>
    <description>Waist circumference (cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Waist circumference</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Waist circumference (cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass Index (BMI)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Body mass Index (BMI)</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>serum creatinine</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle mass</measure>
    <time_frame>Baseline</time_frame>
    <description>Doppler-echocardiograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle mass</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Doppler-echocardiograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Left atrial volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Doppler-echocardiograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Left atrial volume</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Doppler-echocardiograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Doppler echocardiogram velocity ratio</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Doppler echocardiogram velocity ratio</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CRP</measure>
    <time_frame>Baseline</time_frame>
    <description>Inflammatory marker</description>
  </other_outcome>
  <other_outcome>
    <measure>IL6</measure>
    <time_frame>Baseline</time_frame>
    <description>Inflammatory marker</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF alpha</measure>
    <time_frame>Baseline</time_frame>
    <description>Inflammatory marker</description>
  </other_outcome>
  <other_outcome>
    <measure>CRP</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Inflammatory marker</description>
  </other_outcome>
  <other_outcome>
    <measure>IL6</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Inflammatory marker</description>
  </other_outcome>
  <other_outcome>
    <measure>TNF alpha</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Inflammatory marker</description>
  </other_outcome>
  <other_outcome>
    <measure>6- minute walk test</measure>
    <time_frame>Baseline</time_frame>
    <description>Exercise capacity. 6- minute walk test (6 MWT) by the method of Guyatt 43. Percent predicted for age and gender.</description>
  </other_outcome>
  <other_outcome>
    <measure>6- minute walk test</measure>
    <time_frame>After intervention, Week 12</time_frame>
    <description>Exercise capacity. 6- minute walk test (6 MWT) by the method of Guyatt 43. Percent predicted for age and gender.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma nitrate</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Plasma nitrate</measure>
    <time_frame>After intervention, Week 12</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>DASH diet group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive the DASH diet will be prescribed an isocaloric DASH diet using meals (lunch, dinner, snacks) prepared by a Clinical Research Metabolic Kitchen under the direction of a registered dietician. Participants will prepare their own breakfast from a menu. The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Attention Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to attention control will continue their usual diet, but they will be instructed to limit their sodium intake to 2300 mg/day. They will be requested and voluntarily agree to not make additional diet or exercise changes during the 12-week study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DASH Diet</intervention_name>
    <description>12 Weeks of isocaloric DASH diet &lt;2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.</description>
    <arm_group_label>DASH diet group</arm_group_label>
    <other_name>Dietary Approaches to Stop Hypertension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual diet</intervention_name>
    <description>12 weeks usual diet &lt;2300 mg Na/day</description>
    <arm_group_label>Attention Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will have an education level of less than college as a surrogate marker
             of LSES.

        Exclusion Criteria:

          -  Participants should not have a diagnosis of heart failure or loop diuretics on their
             medication list in the EHR or symptoms of dyspnea, edema (assessed via questionnaire)

          -  poorly controlled diabetes mellitus ( HBA 1c &gt;9%)

          -  or uncontrolled hypertension ( SBP&gt;180, DBP&gt;110)

          -  cardiovascular event (MI, stroke, HF, angina, atrial fibrillation) within the previous
             six months

          -  chronic diseases that might interfere with participation (dementia, schizophrenia,
             dialysis or transplant recipient patients)

          -  body-mass index (the weight in kilograms divided by the square of the height in
             meters) of more than 35
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Campos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Campos, MD</last_name>
    <phone>3367139745</phone>
    <email>ccampos@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DASH Diet</keyword>
  <keyword>Low socioeconomic status</keyword>
  <keyword>HFPEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

